Nippon Life Global Investors Americas Inc. Makes New $14.67 Million Investment in Encompass Health Corporation $EHC

Posted by Geri Gentry on Aug 17th, 2026

Nippon Life Global Investors Americas Inc. bought a new position in Encompass Health Corporation (NYSE:EHC – Free Report) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 145,120 shares of the company’s stock, valued at approximately $14,669,000. Nippon Life Global Investors Americas Inc. owned 0.15% of Encompass Health as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also made changes to their positions in EHC. EP Wealth Advisors LLC lifted its position in Encompass Health by 2.4% in the second quarter. EP Wealth Advisors LLC now owns 3,694 shares of the company’s stock valued at $453,000 after purchasing an additional 88 shares during the period. Gamco Investors INC. ET AL boosted its holdings in Encompass Health by 2.0% in the 1st quarter. Gamco Investors INC. ET AL now owns 4,813 shares of the company’s stock valued at $466,000 after purchasing an additional 94 shares in the last quarter. Gibson Capital LLC increased its position in Encompass Health by 4.3% during the 1st quarter. Gibson Capital LLC now owns 2,431 shares of the company’s stock worth $235,000 after purchasing an additional 101 shares during the period. Leuthold Group LLC raised its stake in shares of Encompass Health by 0.3% during the 4th quarter. Leuthold Group LLC now owns 31,168 shares of the company’s stock worth $3,308,000 after buying an additional 104 shares in the last quarter. Finally, Covestor Ltd raised its stake in shares of Encompass Health by 24.4% during the 4th quarter. Covestor Ltd now owns 540 shares of the company’s stock worth $57,000 after buying an additional 106 shares in the last quarter. 97.25% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research firms recently weighed in on EHC. Wall Street Zen upgraded Encompass Health from a “hold” rating to a “buy” rating in a research note on Sunday. UBS Group increased their price objective on Encompass Health from $150.00 to $155.00 and gave the stock a “buy” rating in a research report on Friday, August 7th. Weiss Ratings raised Encompass Health from a “hold (c+)” rating to a “buy (b-)” rating in a report on Wednesday. Leerink Partners set a $152.00 target price on shares of Encompass Health in a research report on Friday, May 22nd. Finally, Barclays upped their price target on shares of Encompass Health from $140.00 to $144.00 and gave the stock an “overweight” rating in a research note on Thursday, August 6th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $148.71.

View Our Latest Stock Report on EHC

Insider Buying and Selling at Encompass Health

In other news, EVP John Patrick Darby sold 8,906 shares of Encompass Health stock in a transaction on Monday, August 10th. The stock was sold at an average price of $125.95, for a total transaction of $1,121,710.70. Following the completion of the transaction, the executive vice president owned 75,041 shares of the company’s stock, valued at $9,451,413.95. The trade was a 10.61% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CEO Mark J. Tarr sold 173,148 shares of the business’s stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $125.47, for a total transaction of $21,724,879.56. Following the completion of the sale, the chief executive officer owned 267,814 shares in the company, valued at $33,602,622.58. This represents a 39.27% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders own 1.80% of the company’s stock.

Encompass Health Price Performance

Shares of NYSE:EHC opened at $123.58 on Monday. The business’s 50 day simple moving average is $109.12 and its 200-day simple moving average is $105.53. The firm has a market capitalization of $12.19 billion, a price-to-earnings ratio of 20.13, a price-to-earnings-growth ratio of 2.51 and a beta of 0.72. The company has a debt-to-equity ratio of 0.76, a current ratio of 1.19 and a quick ratio of 1.19. Encompass Health Corporation has a 12 month low of $92.77 and a 12 month high of $127.99.

Encompass Health (NYSE:EHC – Get Free Report) last released its quarterly earnings data on Wednesday, August 5th. The company reported $1.55 earnings per share for the quarter, beating the consensus estimate of $1.48 by $0.07. The firm had revenue of $1.60 billion during the quarter, compared to the consensus estimate of $1.57 billion. Encompass Health had a return on equity of 18.08% and a net margin of 10.01%.Encompass Health’s quarterly revenue was up 9.6% on a year-over-year basis. During the same period last year, the business posted $1.40 EPS. Encompass Health has set its FY 2026 guidance at 6.020-6.250 EPS. As a group, equities analysts forecast that Encompass Health Corporation will post 6.08 earnings per share for the current fiscal year.

Encompass Health Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, October 15th. Stockholders of record on Thursday, October 1st will be given a $0.21 dividend. This is an increase from Encompass Health’s previous quarterly dividend of $0.19. This represents a $0.84 dividend on an annualized basis and a dividend yield of 0.7%. The ex-dividend date is Thursday, October 1st. Encompass Health’s dividend payout ratio (DPR) is 12.38%.

Encompass Health Profile

(Free Report)

Encompass Health Corporation is a leading provider of post‐acute healthcare services in the United States, operating a comprehensive network of inpatient rehabilitation hospitals and home health and hospice agencies. Its inpatient rehabilitation hospitals offer intensive therapy programs for patients recovering from conditions such as stroke, brain injury, spinal cord injury, cardiac and pulmonary disorders, and orthopedic procedures. Through its home health segment, Encompass Health delivers skilled nursing, physical therapy, occupational therapy and speech therapy to patients in the comfort of their homes, while its hospice services provide end‐of‐life care focused on symptom management and emotional support for patients and families.

Founded in 1984 as HealthSouth Corporation and rebranded as Encompass Health in 2018, the company has grown organically and through acquisitions to serve patients across more than 30 states.